GlassScriptPhysician profile
Ann Cameron Schieber
NPI 1790123164
$8,776.43
in general payments reported to CMS, 2019-2025
27 companies · $2,067 in 2025
The $2,067 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.00 · 2021: $1,069 · 2022: $1,902 · 2023: $1,668 · 2024: $2,046 · 2025: $2,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,601 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,601.08 |
| Education | $180.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,749.81 | 2021-2025 | |
| Genzyme Corporation | $879.26 | 2021-2025 | |
| Janssen Biotech, INC. | $740.89 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $702.62 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $698.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $485.14 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $375.23 | 2021-2025 | Ilumya, Winlevi |
| Ucb, INC. | $352.05 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $333.55 | 2021-2025 | Siliq, Cabtreo |
| Galderma Laboratories, L.P. | $325.28 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Arcutis Biotherapeutics, INC. | $314.91 | 2023-2025 | Zoryve |
| Amgen INC. | $302.75 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $258.86 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $247.41 | 2022-2025 | Sotyktu |
| Incyte Corporation | $216.30 | 2021-2025 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $177.99 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $156.37 | 2021-2025 | |
| Epi Health, LLC | $107.24 | 2021-2022 | |
| Organon LLC | $61.50 | 2025 | Vtama |
| Botanix Sb INC | $55.80 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $53.10 | 2023-2024 | Xtrac |
| Allergan, INC. | $48.54 | 2022 | |
| Biofrontera INC. | $46.90 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Glenmark Therapeutics INC. | $24.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $23.28 | 2024 | Ycanth |
| Merz North America, INC. | $20.75 | 2025 | |
| Lnhc, INC | $18.22 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Schieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.